Nuformix (LON:NFX) Posts Earnings Results

Nuformix (LON:NFX) posted its earnings results on Tuesday. The company reported GBX (0.04) earnings per share (EPS) for the quarter, Digital Look Earnings reports.

Nuformix Stock Down 9.8%

Nuformix stock opened at GBX 0.20 on Thursday. Nuformix has a twelve month low of GBX 0.01 and a twelve month high of GBX 0.56. The company has a market capitalization of £4.28 million, a P/E ratio of -0.52 and a beta of 1.22. The stock’s 50 day moving average is GBX 0.27 and its 200 day moving average is GBX 0.21.

About Nuformix

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.